Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for FDG Positron Emission Tomography (PET) for oncologic conditions, effective May 15, 2026. Here's what billing teams need to do.
CMS FDG PET oncologic imaging coverage policy has a long history of incremental updates — and this 2026 modification continues that pattern. The Centers for Medicare & Medicaid Services governs FDG PET coverage through a National Coverage Determination that affects oncology, nuclear medicine, and radiology practices across every Medicare-participating facility. This policy does not list specific codes in the available policy data, so we've outlined what your team should do now and flagged where to get code-level detail before the effective date of May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Positron Emission Tomography (FDG) for Oncologic Conditions |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Nuclear Medicine, Radiology, Hematology/Oncology, Radiation Oncology |
| Key Action | Review your FDG PET billing workflows and medical necessity documentation against the updated policy before May 15, 2026 |
CMS FDG PET Coverage Criteria and Medical Necessity Requirements 2026
CMS FDG PET coverage for oncologic conditions has always hinged on two things: the cancer type and the clinical indication — diagnosis, staging, restaging, or treatment monitoring. That structure hasn't changed. What billing teams get tripped up on is the tiered coverage model CMS uses for FDG PET, which varies by cancer type and which the 2026 modification may have adjusted.
Under the existing National Coverage Determination framework, CMS recognizes FDG PET as covered for specific oncologic indications where medical necessity is established through documented clinical criteria. Medical necessity documentation must support why the PET scan was ordered, what treatment decision it will inform, and why lower-cost imaging wasn't sufficient. If your clinical staff isn't documenting treatment intent in the order and the clinical notes, you're setting up your billing team for a claim denial.
Prior authorization requirements for FDG PET are not universally required at the Medicare fee-for-service level, but Medicare Advantage plans — which follow their own coverage rules — often impose prior authorization. If your patient mix includes Medicare Advantage, check each plan's requirements separately. Don't assume CMS fee-for-service rules apply to MA plans.
The real issue with this coverage policy is that CMS has historically used a coverage-with-evidence-development (CED) framework for some FDG PET indications. That framework conditions reimbursement on participation in a qualifying registry or clinical trial. If the 2026 modification altered any CED requirements — expanding coverage, lifting restrictions, or adding new cancer types — your billing team needs to know before May 15, 2026. The source policy at app.payerpolicy.org/p/cms/331-v4 is where you get that confirmation.
CMS FDG PET Exclusions and Non-Covered Indications
CMS does not cover FDG PET for every oncologic indication. The existing framework explicitly limits coverage to defined cancer types and clinical scenarios. Indications that fall outside those definitions — or that CMS classifies as not medically necessary — result in non-covered claims.
Historically, coverage gaps have included FDG PET used purely for screening in asymptomatic patients, PET performed for indications that don't meet the documented clinical criteria, and repeat PET scans that lack documentation of changed clinical status. This is where your claim denial risk concentrates.
If a provider orders FDG PET for an indication that doesn't appear in the covered indications framework, your billing team needs to know before the claim goes out — not after it denies. Build that checkpoint into your pre-authorization and charge capture workflow now.
Coverage Indications at a Glance
The available policy data does not include a code-level or indication-level breakdown for this specific 2026 modification. The table below reflects the general CMS FDG PET coverage framework based on the existing NCD structure. Verify each row against the updated policy at app.payerpolicy.org/p/cms/331-v4 before May 15, 2026.
| Indication | Status | Notes |
|---|---|---|
| Initial diagnosis / characterization of malignancy | Covered (for defined cancer types) | Medical necessity documentation required; coverage varies by cancer type |
| Staging of known malignancy | Covered (for defined cancer types) | Must document impact on treatment planning |
| Restaging after treatment | Covered (for defined cancer types) | Requires documentation of prior treatment and clinical rationale |
| Monitoring response to treatment | Covered (for defined cancer types) | Clinical notes must reflect treatment decision context |
| Indications under Coverage with Evidence Development (CED) | Covered only with registry/trial participation | Verify whether 2026 modification changed any CED requirements |
| Oncologic screening in asymptomatic patients | Not Covered | Not a covered Medicare benefit under existing NCD framework |
| Indications outside defined cancer types | Not Covered | Check updated policy for any newly added cancer types |
CMS FDG PET Billing Guidelines and Action Items 2026
The effective date is May 15, 2026. That gives your team a defined window to audit your workflows and fix gaps before claims start processing under the modified policy.
| # | Action Item |
|---|---|
| 1 | Pull the full updated policy text now. The policy data available for this post does not include the line-by-line changes. Go to app.payerpolicy.org/p/cms/331-v4 and read the current version against the prior version. You need to know exactly what changed — not a summary of what might have changed. |
| 2 | Audit your FDG PET charge capture against the updated coverage criteria. Map every FDG PET indication your practice bills to the coverage framework in the 2026 policy. If an indication you've been billing is now restricted — or if a new one is now covered — update your charge capture before May 15, 2026. |
| 3 | Review your medical necessity documentation templates. FDG PET billing requires specific documentation: the clinical indication, the cancer type, the treatment decision the scan will inform. If your templates don't capture all of that, fix them now. A claim denial for lack of medical necessity documentation is avoidable. |
| 4 | Check for any changes to Coverage with Evidence Development requirements. If the 2026 modification changed which indications require registry participation, your billing team and your clinical team both need to know. A claim submitted for a CED indication without registry documentation will deny. Loop in your compliance officer if you're not sure how CED applies to your patient mix. |
| 5 | Separate your Medicare Advantage billing workflow from your fee-for-service workflow. CMS fee-for-service FDG PET billing guidelines do not automatically apply to Medicare Advantage plans. Each MA plan sets its own prior authorization requirements and coverage criteria. Check each plan individually before May 15, 2026. |
| 6 | Train your clinical staff on documentation requirements. The most common FDG PET reimbursement failures trace back to inadequate clinical documentation — not coding errors. The ordering provider needs to document the indication, the cancer type, and the clinical decision being made. If your clinical staff doesn't know what the billing requirements are, that's a gap you fix through training, not through editing claims after the fact. |
| 7 | If you're uncertain about how this modification applies to your specific specialty or payer mix, talk to your compliance officer before May 15, 2026. This policy has financial exposure across oncology, nuclear medicine, and radiology. It's not a low-stakes update. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for FDG PET Oncology Under This Policy
The policy data provided for this post does not list specific CPT, HCPCS, or ICD-10 codes. Do not use this post as your sole source for code-level billing decisions.
FDG PET oncology billing involves a defined set of CPT codes for the scan itself, as well as radiopharmaceutical HCPCS codes for the FDG tracer. These codes — and which ones are covered under which indications — are specified in the full policy. Pull those directly from the updated policy text at app.payerpolicy.org/p/cms/331-v4.
Your billing team should cross-reference those codes against your current charge master and fee schedule before May 15, 2026. If a code appears in the policy as newly covered or newly restricted, that change affects your reimbursement immediately on the effective date.
This is also a good time to verify that your Medicare Administrative Contractor (MAC) hasn't issued a Local Coverage Determination (LCD) that is more restrictive than the CMS national policy. MACs can and do impose tighter criteria than the national NCD. Check your MAC's LCD library for any FDG PET-specific guidance that applies to your region.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.